Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Lifesciences Stock Gains 39% In Q2, Aided By Sapien Valve Sales

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences' report of faster-than-expected European market adoption of its Sapien transcatheter aortic heart valves helped propel a 39% leap in the firm's stock price in the second quarter to $62.04
Advertisement

Related Content

Cordis Pipeline Includes Stents, A-Fib Ablation, Percutaneous AAA Repair
Earnings In Brief
Earnings In Brief
Earnings In Brief
Novartis Sets $39 Billion Path To Purchasing Eye Care Market Leader Alcon
Advertisement
UsernamePublicRestriction

Register

MT026290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel